We are live on ! Find out more

IMGN

Immunogen Inc

IMGN

Market cap $8.72B

Delisted

IMGN was delisted on the 9th of February, 2024.

Back to rankings

About: Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Employees: 277

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 0%

Negative 0%

Zacks Investment Research

Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?

Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

Zacks Investment Research

ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?

ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024

As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry

ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.

Cramer names biopharma companies to watch as industry mergers start to pile up

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Zacks Investment Research

All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy

ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research

Best Momentum Stocks to Buy for January 4th

IMGN and GTLB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2024.

Zacks Investment Research

New Strong Buy Stocks for January 4th

IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Price charts implemented using Lightweight Charts™